Side-by-side comparison of AI visibility scores, market position, and capabilities
Dyno Therapeutics uses AI and high-throughput synthesis to engineer next-generation AAV gene therapy vectors with improved tissue targeting, manufacturability, and immune evasion; raised $100M Series B;
Dyno Therapeutics is a Cambridge, Massachusetts-based gene therapy biotechnology company founded in 2018 by George Church (Harvard), Eric Kelsic, and Sam Sinai. The company's core insight is that the adeno-associated virus (AAV) — the dominant vector for approved gene therapies — has enormous untapped diversity in its capsid protein sequences, and that AI can be used to explore this diversity space far more efficiently than directed evolution or rational design alone. Dyno's platform generates hundreds of thousands of synthetic AAV capsid variants, characterizes their properties in high-throughput cell and animal assays, and uses machine learning to learn the sequence-function relationships that determine tissue targeting, manufacturing yield, and immune evasion.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
Dyno Therapeutics vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.